期刊
JOURNAL OF EXTRACELLULAR VESICLES
卷 9, 期 1, 页码 -出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/20013078.2020.1766192
关键词
Exosomes; HSP70; diagnosis; liquid biopsy; cancer
类别
资金
- French Government grant [ANR-11-LABX-0021-01-LipSTIC]
- Ligue Nationale Contre le Cancer
- Institut National du Cancer
- Centre Georges-Francois Leclerc
- Canceropole Est
- Fondation Silab Jean Paufique
- Regional Council Burgundy/Franche-Comte et FEDER
- Fondation pour la Recherche Medicale [FRM grant] [ECO2016073609]
Exosomes are nanovesicles released by all cells that can be found in the blood. A key point for their use as potential biomarkers in cancer is to differentiate tumour-derived exosomes from other circulating nanovesicles. Heat shock protein-70 (HSP70) has been shown to be abundantly expressed by cancer cells and to be associated with bad prognosis. We previously showed that exosomes derived from cancer cells carried HSP70 in the membrane while those from non-cancerous cells did not. In this work, we opened a prospective clinical pilot study including breast and lung cancer patients to determine whether it was possible to detect and quantify HSP70 exosomes in the blood of patients with solid cancers. We found that circulating exosomal HSP70 levels, but not soluble HSP70, reflected HSP70 content within the tumour biopsies. Circulating HSP70 exosomes increased in metastatic patients compared to non-metastatic patients or healthy volunteers. Further, we demonstrated that HSP70-exosome levels correlated with the disease status and, when compared with circulating tumour cells, were more sensitive tumour dissemination predictors. Finally, our case studies indicated that HSP70-exosome levels inversely correlated with response to the therapy and that, therefore, monitoring changes in circulating exosomal HSP70 might be useful to predict tumour response and clinical outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据